CLPP and cancer: The promising clinical benefits testing dordaviprone in clinical trials, expanded access schemes and through unorthodox routes, coupled with the identification of CLPP overexpression in aggressive cancers including DMG, has stimulated the development of new ClpP agonists called “TR” analogs.